For a client’s botulinum toxin used for spasticity and dystonia. Research and analyse the optimal positioning versus competitors to support potential licence extension. Because the positioning would be influenced by upcoming pivotal trials. These were a focus for the analysis.
ESP reviewed and analysed data for key competitor products. Scientific statements were identified and validated with a scientific communication committee of leading experts. A SWOT and GAP analysis were completed. Resulting insights were synthesized with the unique science for the client’s botulinum toxin to inform development of the optimal positioning. Scientific statements supporting the product were finalised and a plan for supporting sub-analyses developed.
Clear positioning and scientific statements supported by the clinical evidence created by ESP. A publication plan disseminating this evidence was implemented and delivered. The client’s product achieved licence extension approval. Get in touch today to discuss your strategic medical communication needs.